{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T10:03:31Z","timestamp":1768817011321,"version":"3.49.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000097","name":"National Center for Research Resources","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000097","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences (NCATS)","doi-asserted-by":"publisher","award":["1UL1TR001079"],"award-info":[{"award-number":["1UL1TR001079"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["brachyjournal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brachytherapy"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.brachy.2017.10.008","type":"journal-article","created":{"date-parts":[[2017,11,24]],"date-time":"2017-11-24T02:16:44Z","timestamp":1511489804000},"page":"313-318","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Reductions in prostatic doses are associated with less acute morbidity in patients undergoing Pd-103 brachytherapy: Substantiation of the rationale for focal therapy"],"prefix":"10.1016","volume":"17","author":[{"given":"Adam","family":"Ferro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hee Joon","family":"Bae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gayane","family":"Yenokyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Le","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd","family":"McNutt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Mian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol","family":"Gergis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chloe","family":"Haviland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodore L.","family":"DeWeese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel Y.","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.brachy.2017.10.008_bib1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1464-410X.2011.10827.x","article-title":"Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results Prostate Cancer Results Study Group","volume":"109","author":"Grimm","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.brachy.2017.10.008_bib2","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijrobp.2016.11.026","volume":"98","author":"Morris","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2017.10.008_bib3","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0360-3016(01)01811-9","article-title":"The dosimetry of prostate brachytherapy-induced urethral strictures","volume":"52","author":"Merrick","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2017.10.008_bib4","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.ijrobp.2007.12.052","article-title":"Segmental urethral dosimetry and urinary toxicity in patients with no urinary symptoms before permanent prostate brachytherapy","volume":"72","author":"Thomas","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2017.10.008_bib5","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.ijrobp.2004.12.068","article-title":"Detailed urethral dosimetry in the evaluation of prostate brachytherapy-related urinary morbidity","volume":"62","author":"Allen","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2017.10.008_bib6","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.brachy.2007.03.003","article-title":"The nature and extent of urinary morbidity in relation to prostate brachytherapy urethral dosimetry","volume":"6","author":"Neill","year":"2007","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2017.10.008_bib7","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0360-3016(01)02658-X","article-title":"Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation","volume":"52","author":"Crook","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2017.10.008_bib8","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/00130404-200509000-00005","article-title":"I-125 versus Pd-103 for low-risk prostate cancer: long-term morbidity outcomes from a prospective randomized multicenter controlled trial","volume":"11","author":"Herstein","year":"2005","journal-title":"Cancer J"},{"key":"10.1016\/j.brachy.2017.10.008_bib9","first-page":"221","article-title":"The behavior of maximum likelihood estimates under nonstandard conditions","volume":"vol 1","author":"Huber","year":"1967"},{"key":"10.1016\/j.brachy.2017.10.008_bib10","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1177\/1536867X1201200209","article-title":"Using the margins command to estimate and interpret adjusted predictions and marginal effects","volume":"12","author":"Williams","year":"2012","journal-title":"Stata J"},{"key":"10.1016\/j.brachy.2017.10.008_bib11","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1097\/01.ju.0000152698.20487.0e","article-title":"Urinary morbidity and incontinence following transurethral resection of the prostate after brachytherapy","volume":"173","author":"Kollmeier","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.brachy.2017.10.008_bib12","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.ijrobp.2005.03.046","article-title":"Quality of life of patients after permanent prostate brachytherapy in relation to dosimetry","volume":"63","author":"Van Gellekom","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2017.10.008_bib13","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.brachy.2017.04.242","article-title":"Clinical factors and dosimetry associated with the development of prostate brachytherapy-related urethral strictures: A matched case-control study","volume":"16","author":"Singhal","year":"2017","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2017.10.008_bib14","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.ijrobp.2014.06.031","article-title":"Dose to the bladder neck is the most important predictor for acute and late toxicity after low-dose-rate prostate brachytherapy: Implications for establishing new dose constraints for treatment planning","volume":"90","author":"Hathout","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2017.10.008_bib15","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1007\/s00066-006-1530-z","article-title":"Health-related quality of life after permanent interstitial brachytherapy for prostate cancer: Correlation with postimplant CT scan parameters","volume":"182","author":"Pinkawa","year":"2006","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.brachy.2017.10.008_bib16","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.ijrobp.2015.02.043","article-title":"Dosimetry modeling for focal low-dose-rate prostate brachytherapy","volume":"92","author":"Al-Qaisieh","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2017.10.008_bib17","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.brachy.2013.02.002","article-title":"Focal brachytherapy for selected low-risk prostate cancers: A pilot study","volume":"12","author":"Cosset","year":"2013","journal-title":"Brachytherapy"}],"container-title":["Brachytherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153847211730483X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153847211730483X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T02:14:32Z","timestamp":1761531272000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S153847211730483X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S153847211730483X"],"URL":"https:\/\/doi.org\/10.1016\/j.brachy.2017.10.008","relation":{},"ISSN":["1538-4721"],"issn-type":[{"value":"1538-4721","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reductions in prostatic doses are associated with less acute morbidity in patients undergoing Pd-103 brachytherapy: Substantiation of the rationale for focal therapy","name":"articletitle","label":"Article Title"},{"value":"Brachytherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.brachy.2017.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}